MOTS-c Peptide Research and Its 2026 HHS Compounding Status

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. Human research has measured MOTS-c levels during exercise, aging, diabetes, and obesity, but researchers have not tested MOTS-c treatment in a completed human clinical trial. Most metabolic claims come from mice. A short human trial tested CB4211, a modified analogue, rather than MOTS-c itself. The U.S. Food and Drug Administration (FDA) states that MOTS-c’s molecular targets remain unknown and that human safety and effectiveness cannot be determined from current evidence.^1,2 The U.S. Department of Health and Human Services (HHS) released a draft enforcement-discretion policy on October 28, 2026. It covers single-ingredient MOTS-c acetate for subcutaneous or intramuscular injection, compounded by a state-licensed pharmacy or licensed physician on a patient-specific prescription.¹³ That policy is not an FDA approval, and your physician decides from your labs whether MOTS-c fits your metabolic picture.

MOTS-c Biology and Current Human Evidence

MOTS-c is a mitochondrial-derived peptide first reported in 2015. It is encoded by a short open reading frame within the mitochondrial 12S ribosomal ribonucleic acid gene.¹ Mitochondria are structures inside cells that help produce energy.

The original research linked MOTS-c with metabolic regulation in mice. In mice fed a high-fat diet, MOTS-c prevented obesity and insulin resistance through a pathway involving adenosine monophosphate-activated protein kinase (AMPK), an enzyme involved in cellular energy sensing.¹

Those findings explain the interest in MOTS-c peptide benefits. They do not show that an MOTS-c injection produces the same effects in you.

Using a metabolic peptide to chase weight or glucose can leave the underlying drivers unmeasured. A 55+ biomarker panel can put glucose, insulin resistance, and lipids into a broader metabolic pattern.

The FDA’s 2026 briefing document describes MOTS-c as a naturally occurring mitochondrial hexadecapeptide, which means a peptide containing 16 amino acids. The FDA also states that its molecular targets remain unknown. The agency found no clinical studies or human exposure data for MOTS-c through any route.²

Current human research is observational. Researchers have measured MOTS-c already present in blood or muscle, but they did not give participants MOTS-c as a treatment. That distinction changes how you should read every claimed benefit.

Human Observational Findings

Human studies associate MOTS-c levels with exercise, age, diabetes, and obesity. The results do not yet form one consistent pattern you could use to judge your own metabolic health.

In a study of 10 sedentary healthy young men, muscle MOTS-c increased after cycling intervals. Plasma levels also rose during and after exercise before returning to baseline within four hours.³ This shows that MOTS-c responds to acute exercise in a small male sample. It does not show that injected MOTS-c would improve your exercise performance.

Age-related findings also depend on where MOTS-c was measured. In healthy men across three age groups, circulating MOTS-c was lower with age. MOTS-c measured in skeletal muscle was higher in middle-aged and older participants than in younger participants.⁴ In that study, blood and muscle MOTS-c moved in opposite directions with age.

Metabolic findings conflict across populations. A study of 225 adults found lower serum MOTS-c in people with type 2 diabetes than in controls.⁵ Another study found lower circulating MOTS-c in boys with obesity compared with controls, while girls showed no difference.⁶

One MOTS-c level is a data point. Your physician needs the surrounding metabolic markers to decide whether the result belongs to a broader pattern.

A 2026 study found the opposite direction in adults. Among 32 adults with obesity and 22 lean controls, circulating MOTS-c was higher in the group with obesity. Levels did not change after bariatric surgery, and the authors described the findings as preliminary.⁷

Age, sex, tissue, metabolic status, and laboratory method may all affect the result. Your physician would need to consider the entire pattern before treating one MOTS-c measurement as clinically useful.

Evidence Table for MOTS-c Claims

Each MOTS-c claim you read rests on one of three kinds of evidence: human observation, analogue testing, or animal experiments.

A study can be relevant without answering whether MOTS-c treatment works in people. Human observation can identify an association. An analogue trial can support further research. Mouse experiments can test a mechanism. None of those substitutes for a human clinical trial of MOTS-c itself. Before you act on a MOTS-c claim, ask your physician which of these study types stands behind it.

CB4211 Analogue Trial

CB4211 is a modified analogue described by its developer as a novel and improved analogue of MOTS-c. CB4211 is not MOTS-c.

CohBar reported results from a randomized, double-blind, placebo-controlled phase 1b trial in adults with obesity and fatty liver. The trial lasted four weeks and included 20 participants who completed it, with 11 receiving CB4211 and nine receiving placebo.⁸

The company reported no serious adverse events. Injection-site reactions occurred in 79% of participants receiving CB4211 and 33% receiving placebo. Alanine aminotransferase (ALT) fell 21% with CB4211 and rose 4% with placebo. Aspartate aminotransferase (AST) fell 28% and 11%, respectively. Fasting glucose fell 6% with CB4211 and did not change with placebo.⁸

Liver fat decreased in both groups without a meaningful difference between them. Body weight showed a trend, but the difference was not statistically conclusive.⁸

These results were reported by the company and have not appeared in a peer-reviewed paper. The ClinicalTrials.gov record posts no trial results.⁹ CB4211 data cannot establish the effects or safety of compounded MOTS-c. If weight loss is your goal, your physician can weigh that thin record against FDA-approved obesity treatments, which FDA’s briefing notes already exist.²

Animal Research Behind Metabolic Claims

Animal studies account for the main weight, glucose, and fat-loss claims associated with MOTS-c. These experiments help researchers choose questions for human trials.

In obese mice, three days of MOTS-c treatment lowered blood glucose and changed plasma metabolites.¹⁰ In ovariectomized female mice, MOTS-c reduced weight gain and fat accumulation.¹¹ The original 2015 study also reported protection against diet-induced obesity and insulin resistance in mice.¹

Mouse physiology can reveal a possible mechanism, but it cannot tell you whether you will lose body fat after an MOTS-c injection. The FDA concluded that evidence is insufficient to evaluate the effectiveness of MOTS-c-related bulk drug substances for the nominated uses.²

A fixed peptide protocol does not account for your baseline glucose, insulin resistance, or lipids. Repeat testing lets your physician adjust a plan based on what changed.

Other metabolic peptides have different mechanisms and separate evidence records. 5-amino-1MQ should be evaluated on its own data rather than grouped with MOTS-c.

MOTS-c Side Effects and Safety Evidence

MOTS-c side effects in people have not been characterized through completed clinical trials. The FDA found no clinical studies or human exposure data for MOTS-c through any route of administration.²

The CB4211 trial provides information about a modified analogue. Its injection-site reaction rate cannot be assigned to MOTS-c because the two compounds are different.⁸

The FDA also raised concern about possible immunogenicity with injected MOTS-c-related substances.² Immunogenicity means an unwanted immune response to a substance. The briefing does not establish how often such a reaction occurs in people because the necessary human data do not exist.

Laboratory stability creates another question. MOTS-c broke down quickly in human whole blood in an in vitro study. The FDA said this raises uncertainty about whether externally administered MOTS-c can reach pharmacologically active concentrations.²

Measurement methods also disagree. A doping-control study found that mass spectrometry could not confirm the MOTS-c levels reported by a commercial enzyme-linked immunosorbent assay (ELISA) kit. The two methods produced considerably different results.¹² Your physician should be cautious about making a treatment decision from an isolated MOTS-c result.

Federal Policy and Injectable Routes

The October 2026 Department of Health and Human Services (HHS) policy describes limited enforcement discretion for certain compounded peptide products. It does not approve MOTS-c or add it to the 503A bulks list.

The HHS policy includes MOTS-c acetate in Appendix A. Appendix B lists only subcutaneous or intramuscular injectable dosage forms for MOTS-c acetate. Oral MOTS-c and tablets are outside the listed route.¹³

The policy applies to a MOTS-c product you are prescribed only when all stated conditions are present. These include a patient-specific prescription, a single active ingredient, sourcing and testing requirements, specified labeling, and adverse-event reporting. Research-use-only products and online peptide sellers are not covered.¹³

HHS describes the policy as interim enforcement discretion while the FDA reviews the substances. The Federal Register notice states that the draft creates no rights and is not binding on HHS or the public.¹⁴ Compounded drugs are not FDA-approved, so the FDA does not review their safety, effectiveness, or quality before marketing.^13,14

The policy includes six peptides. The broader status and route details appear in our peptide policy review, including Epitalon as the other healthy-aging peptide on the list.

Athletic Eligibility

MOTS-c is prohibited at all times for athletes subject to anti-doping rules. The U.S. Anti-Doping Agency (USADA) places it under Section 4.4 Metabolic Modulators, subsection 4.4.1.¹⁵

USADA also states that safe conditions of use are unknown because there are no completed human clinical trials.¹⁵ If you compete under anti-doping rules, raise your testing status with your physician before any peptide is discussed.

The Opt Take on MOTS-c

At Opt Health, every lab we order gets read by a physician before anyone is offered a treatment. The process starts with a 55+ biomarker panel completed at home or at a partner lab, followed by a 1:1 physician review.

That review puts glucose, insulin resistance, and lipids alongside your existing conditions and current medications. Your physician can weigh approved treatment options first and decide whether the evidence for an experimental peptide supports further discussion.

A full panel and physician consultation repeat every 3 to 4 months, so the plan can be adjusted to the numbers that changed. One MOTS-c result cannot replace that metabolic pattern.

Physician-guided peptide therapy begins with your baseline and continues with monitoring. Your plan should respond to your data rather than to mouse results or before-and-after photos.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.